My Alcon | Language

This page is available in English. Select below for other countries.

Select another country

One powerful drop starts with ROCKLATAN®

(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

Layers of the eye graphic
Layers of the eye graphic

Mechanisms of Action

 

See how ROCKLATAN® increases outflow through 2 pathways1

An elder woman stretching before a run wearing ear buds.
An elder woman stretching before a run wearing ear buds.

Safety & Dosing Considerations

 

Educate your patients about what to expect with ROCKLATAN®

Alcon savings card
Alcon savings card

Savings & Support

 

Alcon is committed to supporting patient access to medications

MOAs=Mechanisms of action. 

 

REFERENCE  
 

1. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327-338.

 

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

  • Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

INDICATIONS AND USAGE

 

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.
  • Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.
  • Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.
  • Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.
  • Remove contact lenses prior to administration and reinsert 15 minutes after administration.

 

INDICATIONS AND USAGE

 

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

 

Adverse Reactions

 

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

 

DOSAGE AND ADMINISTRATION

 

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

 

Please click here for full prescribing information for ROCKLATAN® Solution.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.